Last Update: 2023-12-23 06:00:12
Cytek Biosciences Inc. ( CTKB ) https://cytekbio.com
Medical Devices
United States
Historical Returns*:
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Other Earnings and Cash Flow Stats:
Cytek Biosciences Inc. ( CTKB ) Net Income TTM ($MM) is -8.07
Cytek Biosciences Inc. ( CTKB ) Operating Income TTM ($MM) is -13.15
Cytek Biosciences Inc. ( CTKB ) Owners' Earnings Annual ($MM) is 0.00
Cytek Biosciences Inc. ( CTKB ) Current Price to Owners' Earnings ratio is 0.00
Cytek Biosciences Inc. ( CTKB ) EBITDA TTM ($MM) is -7.77
Cytek Biosciences Inc. ( CTKB ) EBITDA Margin is -9.68%
Capital Allocation:
Cytek Biosciences Inc. ( CTKB ) has paid 0.00 dividends per share and bought back 2.536057 million shares in the past 12 months
Cytek Biosciences Inc. ( CTKB ) has increased its debt by 16.65 million USD in the last 12 months
Capital Structure:
Cytek Biosciences Inc. ( CTKB ) Interest-bearing Debt ($MM) as of last quarter is 32
Cytek Biosciences Inc. ( CTKB ) Annual Working Capital Investments ($MM) are -117
Cytek Biosciences Inc. ( CTKB ) Book Value ($MM) as of last quarter is 415
Cytek Biosciences Inc. ( CTKB ) Debt/Capital as of last quarter is 7%
Other Balance Sheet Stats:
Cytek Biosciences Inc. ( CTKB ) has 163 million in cash on hand as of last quarter
Cytek Biosciences Inc. ( CTKB ) has 58 million of liabilities due within 12 months, and long term debt 2 as of last quarter
Cytek Biosciences Inc. ( CTKB ) has 136 common shares outstanding as of last quarter
Cytek Biosciences Inc. ( CTKB ) has 0 million USD of preferred stock value
Academic Scores:
Cytek Biosciences Inc. ( CTKB ) Altman Z-Score is 8.41 as of last quarter
Cytek Biosciences Inc. ( CTKB ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Cytek Biosciences Inc. ( CTKB ) largest shareholder is owning shares at 0.00 ($MM) value
Patrik Jeanmonod(an insider) Sold 3000 shares of Cytek Biosciences Inc. ( CTKB ) for the amount of $20820.00 on 2023-11-24
11.57% of Cytek Biosciences Inc. ( CTKB ) is held by insiders, and 55.20% is held by institutions
Cytek Biosciences Inc. ( CTKB ) went public on 2021-07-23
Other Cytek Biosciences Inc. ( CTKB ) financial metrics:
Unlevered Free Cash Flow:-457.01
Operating Margin:-13.38
Gross Profit Margin:56.62
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-6.21
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Cytek Biosciences Inc. ( CTKB ) :
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
User Content from Tickernomics. Created by Luminus.

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.